



**David König**

**Contact**

David König

## Publications (3)

Wyss N, Berner F, Walter V, Jochum A, Purde M, Abdou M, Sinnberg T, Hofmeister K, Pop O, Hasan A, Bauer J, Cheng H, Lütge M, Klümper N, Diem S, Kosaloglu-Yalcin Z, Zhang Y, Sellmer L, Macek B, Karbach J, König D, Läubli H, Zender L, Meyer B, Driessen C, Schürch C, Jochum W, Amaral T, Heinzerling L, Cozzio A, Hegazy A, Schneider T, Brutsche M, Sette A, Lenz T, Walz J, Rammensee H, Früh M, Jäger E, Becher B, Tufman A, Núñez N, Jörger M, Flatz L. Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade. *Am J Respir Crit Care Med* 2024; 210:919–930.

Froesch P, Früh M, Gautschi O, Sessa C, König D, Metaxas Y, Colombo I, Schmid S, Oppliger Leibundgut E, Rusterholz C, Godar G, Li Q, Rothschild S, Mark M, Swiss Group for Clinical Cancer Research (SAKK). Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. *Lung Cancer* 2021; 156:91–99.

Schmid S, Jochum W, Addeo A, Demmer I, Schär S, Janthur W, Wannesson L, König D, Britschgi C, Frösch P, Bouchaab H, Rothschild S, Blum V, Friedlaender A, Mauti L, Früh M. Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort. *Cancer Immunol Immunother* 2020; 69:1605–1613.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)